Eagle flies on Teva bendamustine deal; FDA OK pending

Shares of Eagle Pharmaceuticals soared over 25% on 17 February on word the company had not only kissed and made up with Teva and its subsidiary Cephalon, but had in fact inked a deal involving a rapid infusion form of bendamustine.